Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - olmesartan medoxomil - film coated tablet - 10 milligram - olmesartan medoxomil

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - olmesartan medoxomil - film coated tablet - 20 milligram - olmesartan medoxomil

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - olmesartan medoxomil - film coated tablet - 40 milligram - olmesartan medoxomil

Ireland - English - HPRA (Health Products Regulatory Authority)

stada arzneimittel ag - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 20 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

stada arzneimittel ag - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 20 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

stada arzneimittel ag - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 40 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

stada arzneimittel ag - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 40 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; amlodipine besilate, quantity: 13.888 mg/mg (equivalent: amlodipine, qty mg); hydrochlorothiazide, quantity: 25 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - olmesartan/ amlodipine hct - myl is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty mg) - tablet - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - olmesartan/ amlodipine hct - myl is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 20 mg; amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty mg); hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - olmesartan/ amlodipine hct - myl is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy